A cavitation seed for drug delivery, and a drug delivery method using the same are disclosed. The cavitation seed according to the present invention comprises: a shell which forms the outer surface thereof to maintain the outer shape thereof within a fluid; and a core which is located inside the shell to determine buoyancy of the cavitation seed within the fluid. The cavitation seed can improve an effect of delivering a drug into a body since cavitation is induced by ultrasound at a position close to the epidermis. In addition, the cavitation seed can be applied in the delivery of various drugs as well as skin cosmetics, such as skin tone lightening agents, depilatories, hair restorers and skin fillers, skin analgesics, local anesthetics, agents for genetic diseases such as psoriasis, and agents for treatment of skin disease such as skin cancer.

Residual, refractory or relapsed cancer is treated by immunostimulation in the presence of allogeneic immune effector cells, optimally in combination with radiation therapy. The methods of the disclosure induce a systemic allogeneic anti-tumor immune response that results in tumor regression in untreated sites of disease, i.e. non-injected, non-irradiated, etc.

A system and method for controlling a renal therapy device is provided. The system comprises a controller for performing a method comprising: receiving a first power level of a first battery to determine if the first power level of the first battery is above a threshold value and receiving a second power level of a second battery to determine if the second power level of the second battery is above the threshold value. When the first power level is above the threshold value, the controller causes the renal therapy device to be powered by the first battery. When the first power level is below the threshold value, and the second power level is above the threshold value, the controller causes the renal therapy device to be powered by the second battery. The first battery is electrically isolated from the second battery.

The present invention relates to an ultrasound contrast agent for use in treating a retina disorder by transiently disrupting the blood-retinal barrier (BRB) of a human, wherein the ultrasound contrast agent is administered just before and/or during the application, to the retina of the human, of an unfocused ultrasound (US) beam. The present invention further relates to a therapeutically active agent for use in treating a retina disorder in a human, wherein the therapeutically active agent is to be delivered in combination with an ultrasound contrast agent, which is administered before and/or during the application, to the retina of the human, of an unfocused ultrasound (US) beam in order to transiently disrupting the blood-retinal barrier (BRB) of the human, to allow the therapeutically active agent to cross the BRB and to target the retina. The present invention also relates to an eye ultrasound delivery device that may be used to treat a retina disorder.

An infusion system comprises an infusion set (30) with one or more advanced features including tube set strain relief (10), infusion pumps having heat exchange abilities and two-direction pumping abilities (100), Piezo pump devices (200), reservoirs (220, 240) made from expanded tubing, and oil impregnated pump plungers (302). An exemplary strain relief (10) includes an adhesive layer (12) such as pressure sensitive adhesive (PSA) secured to a base (14). The base (14) rotatably receives a pin (18) of a tube holder (16). The pin (18) is captured within an opening (22) of the base (14) to allow 360 degree rotation of the tube holder (16).

Methods for transdermal delivery of glycosaminoglycans (GAGs) are disclosed, comprising applying ultrasound to the skin followed by topical administration of one or more GAGs optionally complexed with a polysaccharide carrier. When GAG is hyaluronic acid complexed with a modified starch, a transdermal delivery method is provided for facilitating delivery of high molecular weight hyaluronic acid into deep layers of the epidermis and to the dermis in a non-invasive, convenient and painless way. This transdermal delivery method may be applied in treatment of skin aging phenomena associated with collagen and/or hyaluronic acid depletion or loss.

System for inducing sonoporation of a drug into cancer cells in a tumor and method thereof, the system comprising a generator configured to provide electrical energy at an ultrasound frequency; an ultrasound probe electrically connected to the generator and configured to convert the electrical energy into low intensity pulsed ultrasonic waves defined by operation parameters, said operation parameters comprising the frequency, the duty cycle, the operation time of the ultrasonic waves; an input device enabling an operator to enter configuration data comprising: type of tumor, type of drug, localization of secondary tumor, anthropometric measurements and grade of tumor, and a processor configured to determine the values of the operation parameters on the basis of the entered configuration data and control the generator and the ultrasound probe to operate according to said determined values, wherein the value of the frequency is determined on the basis of the type of tumor, the localization of the tumor, the grade of tumor and the anthropometric measurements, the value of the duty cycle is determined on the basis of the drug, the type of tumor and the grade of the tumor, and the value of said operation time being determined on the basis of at least the type of tumor and the type of drug.

The system and process of therapeutic and effective cavitation by using ultrasound to collapse gas vesicles as well as cavitate the bubbles produced from the collapsed gas vesicles. Therapeutic effect includes, but is not limited to lysing cells by cavitation. The cells expressing the gas vesicles can optionally be used as delivery cells to preform tasks such as transporting the gas vesicles into deep tissue areas, releasing compounds at the cavitation site, and more. The gas vesicles can optionally be modified to facilitate getting the bubbles near the cavitation targets by functionalizing the gas vesicles.

An ultrasound catheter system and a method for operating an ultrasonic catheter at a treatment site within a patient's vasculature or tissue are disclosed. The ultrasound catheter system comprises a catheter having at least one ultrasonic element and a control system configured to generate power parameters that drive the at least one ultrasonic element to generate ultrasonic energy. The control system is configured to vary at least one of the power parameters and at least one physiological parameter by repeatedly cycling the power parameter and the physiological parameter through two set of values.

Systems and methods for temporarily altering a tissue characteristic at a target region, such as the blood-brain barrier, include causing an ultrasound transducer to transmit acoustic energy to the target region at a transmission frequency; acquiring a cumulative harmonic response from at least the target region; and operating the transducer based at least in part on the acquired cumulative harmonic response.